Gefördert durch

Fachbücher

Beiträge in Fachzeitschriften und Fachbüchern 2024

  • Fietz A-K, Onken M, Padberg S, Schaefer C, Dathe K. Impact of maternal first trimester treatment regimen on the outcome of valproate exposed pregnancies: an observational Embryotox cohort study. Sci Rep. 2024; 14(1):674
  • Hoeltzenbein M, Bartz I, Fietz A-K, Lohse L, Onken M, Dathe K, Schaefer C. Antiepileptic treatment with levetiracetam during the first trimester and pregnancy outcome: An observational study. Epilepsia. 2024; 65(1):26-36

Beiträge in Fachzeitschriften und Fachbüchern 2023

  • Onken M, Lohse L, Coulm B, Beghin D, Richardson JL, Bermejo-Sánchez E, Aguilera C, Bosch M, Cassina M, Chouchana L, De Santis M, Duman MK, Gören MZ, Johnson D, Bera APJ, Kaplan YC, Kennedy D, Kwok S, Lacroix I, Lepelley M, Pistelli A, Schaefer C, Te Winkel B, Uysal N, Winterfeld U, Yakuwa N, Diav-Citrin O, Vial T, Dathe K. Effects of maternal modafinil treatment on fetal development and neonatal growth parameters - a multicenter case series of the European Network of Teratology Information Services (ENTIS). Acta Psychiatr Scand. 2023;
  • Kittel-Schneider S, Onken M. Psychische Erkrankung und Schwangerschaft. In: Voderholzer U, editor. Therapie psychischer Erkrankungen. 19th ed: Elsevier; 2023. p. 672-5
  • Onken M, Müller A, Metke F, Beck E, Schaefer C, Dathe K. The information platform embryotox.de in routine healthcare – an evaluation project [Abstract]. Z Geburtshilfe Neonatol. 2023; 227(S 01):e148-e9
  • Metke F, Müller A, Beck E, Breuning M, Holmberg C, Schaefer C, Dathe K, Onken M. Antidepressant treatment in pregnancy and lactation: use of embryotox fact sheets in routine healthcare [Abstract]. Z Geburtshilfe Neonatol. 2023; 227(S 01):e235-e6
  • Onken M. Therapie der Zwangsstörung während der Schwangerschaft und postapartal. In: Voderholzer U, Kathmann N, Reuter B, editors. Praxishandbuch Zwangsstörung. 1st ed: Urban & Fischer Verlag / Elsevier GmbH; 2023. p. 262-5
  • Stegherr R, Fietz A-K, Hoeltzenbein M, Dathe K, Beyersmann J. How to account for early overly small risk sets in the analysis of pregnancy outcome data?-Comparison of different methods for stabilizing the Aalen-Johansen estimator. Pharmacoepidemiol Drug Saf. 2023;
  • Müller A, Metke F, Breuning M, Holmberg C, Schaefer C, Onken M, Dathe K. Barriers for using embryotox.de in healthcare practice: Results from qualitative semi-structured interviews of patients and medical doctors [Abstract]. 22 Deutscher Kongress für Versorgungsforschung. 2023 Available from: https://www.egms.de/static/en/meetings/dkvf2023/23dkvf110.shtml.
  • Loibl S, Azim HA, Jr., Bachelot T, Berveiller P, Bosch A, Cardonick E, Denkert C, Halaska MJ, Hoeltzenbein M, Johansson ALV, Maggen C, Markert UR, Peccatori F, Poortmans P, Saloustros E, Saura C, Schmid P, Stamatakis E, van den Heuvel-Eibrink M, van Gerwen M, Vandecaveye V, Pentheroudakis G, Curigliano G, Amant F. ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC). Ann Oncol. 2023
  • Wahliß A, Kayser A, Beck E, Dathe K. Pregnancy outcome after erenumab treatment during early pregnancy: A case series. Neurotoxicology and Teratology. 2023; 98:14-5 [Abstract]
  • Padberg S, Kayser A, Stegherr R, Dathe K. An observational study on safety of COVID-19 vaccines in pregnancy – Current status and preliminary data based on the Embryotox cohort. Neurotoxicology and Teratology. 2023; 98:28 [Abstract]
  • Hoeltzenbein M, Slimi S, Fietz A-K, Stegherr R, Onken M, Beyersmann J, Dathe K, Schaefer C. Increasing use of newer antiseizure medication during pregnancy: An observational study with special focus on lacosamide. Seizure. 2023; 107:107-13
  • Weber-Schoendorfer C, Diav-Citrin O. Methotrexate in pregnancy: still many unanswered questions. RMD Open. 2023; 9(1):e002899
  • Haug U, Kollhorst B, Schink T, Thöne K, Dathe K, Schaefer C, Onken M. Investigating drug safety in pregnancy based on the German Pharmacoepidemiological Research Database (GePaRD): A proof-of-concept analysis on the association between valproate and spina bifida. Pharmacoepidemiol Drug Saf. 2023; 32(2):148-57

Beiträge in Fachzeitschriften und Fachbüchern 2022

  • Panchaud A, Cleary B, Weber-Schoendorfer C, Shechtman S, Cassina M, Diav-Citrin O, Damkier P. The risk of questioning the safety of drugs considered safe in pregnancy at the era of big data: the everlasting case of doxylamine. Journal of clinical epidemiology. 2022; 152:125-6
  • Weber-Schoendorfer C, Dathe K. Teratogene Risiken von Arzneistoffen und beauflagte Schulungsmaterialien des BfArM – wie bekannt sind sie? Ein interviewbasiertes Projekt. Bull Arzneimittelsicherheit. 2022; 2022(3):16-23
  • Dathe K, Frank J, Padberg S, Hultzsch S, Beck E, Schaefer C. Fetal adverse effects following NSAID or metamizole exposure in the 2nd and 3rd trimester: an evaluation of the German Embryotox cohort. BMC Pregnancy and Childbirth. 2022; 22(1):666
  • Stegherr R, Beck E, Hultzsch S, Schaefer C, Dathe K. Can non-responding mask or mimic drug effects on pregnancy outcome? Evaluation of case characteristics based on the national Embryotox cohort. Reprod Toxicol. 2022; 111:129-34
  • Stegherr R, Kayser A, Padberg S, Dathe K. Potential sources of bias in the analysis of COVID-19 vaccine safety during pregnancy: How the embryotox study plans to avoid them by design and analysis methods [Abstract]. Neurotoxicology and Teratology. 2022; 92:107108
  • Hoeltzenbein M, Slimi S, Fietz A-K, Onken M, Dathe K, Schaefer C. Antiseizure medication use during pregnancy, trends over time and individual treatment pattern: An evaluation of the German Embryotox Cohort [Abstract]. Neurotoxicology and Teratology. 2022; 92:107108
  • Schaefer C. Präventiver Mutterschutz (Folge 2). ASU - Zeitschrift für medizinische Prävention. 2022; 57(06):352-5
  • Damkier P, Cleary B, Weber-Schoendorfer C, Shechtman S, Cassina M, Panchaud A, Diav-Citrin O. Handle with care — interpretation, synthesis and dissemination of data on paracetamol in pregnancy. Nat Rev Endocrinol. 2022; 18(3):191
  • Kittel-Schneider S, Onken M. Psychische Erkrankung und Schwangerschaft. In: Voderholzer U, Hohagen F, editors. Therapie psychischer Erkrankungen. 17. ed. München: Urban & Fischer in Elsevier; 2022. p. 619-23

Beiträge in Fachzeitschriften und Fachbüchern 2021

  • Hoeltzenbein M, Dirk I, Slimi S, Fietz A-K, Onken M, Dathe K, Schaefer C. Trends in antiepileptic drug use in pregnancy from 2000–2018 and pregnancy outcome of levetiracetam exposed pregnancies. (P 045). [Abstract] Z Geburtsh Neonatal. 2021; 225(S 01):e46
  • Schaefer C. Wenig Neues zur Ondansetron-Sicherheit. Ein Gastkommentar. DAZ online. 2021; (38):30
  • Onken M, Kayser A. Psychopharmaka in Schwangerschaft und Stillzeit. Hebammen Wissen. 2021; 2(3):36-9
  • Hultzsch S, Paulus W, Padberg S, Fietz A-K, Schaefer C, Dathe K. First trimester naproxen exposure and outcome of pregnancy – A German case series. Reprod Toxicol. 2021; 103:51-7
  • Schaefer C. HNO-Heilkunde in Klinik und Praxis. Arzneimittel in Schwangerschaft und Stillperiode. In: Reiß M, editor. Facharztwissen HNO-Heilkunde: Differenzierte Diagnostik und Therapie. Berlin, Heidelberg 2021. p. 1299-302
  • Hoeltzenbein M, Lehmann M-L, Beck E, Dathe K, Schaefer C. Ivabradine use in pregnant women—treatment indications and pregnancy outcome: an evaluation of the German Embryotox database. Eur J Clin Pharmacol. 2021
  • Hoeltzenbein M, Slimi S, Fietz A-K, Onken M, Dathe K, Schaefer C. Trends in Antiepileptic Drug Use and individual Treatment Pattern during the First Trimester of Pregnancy: An Evaluation of the German Embryotox Cohort [Abstract]. Birth Defects Res. 2021; 113(10):769
  • Maaß N, Dathe K. Off-Label-Einsatz von Medikamenten in der Schwangerschaft. Gynäkologie und Geburtshilfe. 2021; 26(3):36-9
  • Damkier P, Kaplan YC, Shechtman S, Diav-Citrin O, Cassina M, Weber-Schoendorfer C. Ondansetron in pregnancy revisited: Assessment and pregnancy labelling by the European Medicines Agency (EMA) Pharmacovigilance Risk Assessment Committee (PRAC). Basic Clin Pharmacol Toxicol. 2021; 128(4):579-82
  • Pauliat E, Onken M, Weber-Schoendorfer C, Rousson V, Addor M-C, Baud D, Théaudin M, Diav-Citrin O, Cottin J, Agusti A, Rollason V, Kaplan YC, Kennedy D, Kadioglu M, Rothuizen LE, Livio F, Buclin T, Panchaud A, Winterfeld U. Pregnancy outcome following first-trimester exposure to fingolimod: A collaborative ENTIS study. Mult Scler. 2021; 27(3):475-8
  • Schaefer C. Managing a patient exposed to a teratogenic drug at different stages of pregnancy In: Schreiber K, Chakravarty E, Østensen M, editors. Practical management of the pregnant patient with rheumatic disease. Oxford, UK: Oxford University Press; 2021. p. 85-92
  • Damkier P, Kaplan YC, Shechtman S, Diav-Citrin O, Cassina M, Weber-Schoendorfer C, Cleary B, Hodson K. Ondansetron should never be used in pregnancy. Against: Ondansetron in prgnancy revisited. BJOG. 2021; 128(1):111-2
  • Kittel-Schneider S, Dorsch VM, Onken M. Psychische Erkrankung und Schwangerschaft. In: Voderholzer U, Hohagen F, editors. Therapie psychischer Erkrankungen. 16., aktualisierte und erweiterte Auflage ed. München: Urban & Fischer in Elsevier; 2021. p. 649-53

Beiträge in Fachzeitschriften und Fachbüchern 2020

  • Hoeltzenbein M, Wagner JK, Schaefer C, Dathe K. Pregnancy outcome after failure of emergency contraception with ulipristal acetate - an observational study [Abstract]. Eur J Hum Genet. 2020; 28(Suppl 1):180
  • Beyer-Westendorf J, Tittl L, Bistervels I, Middeldorp S, Schaefer C, Paulus W, Thomas W, Kemkes-Matthes B, Marten S, Bornhauser M. Safety of direct oral anticoagulant exposure during pregnancy: a retrospective cohort study. The Lancet Haematology. 2020; 7(12):e884-e91
  • Dirk I, Hüttel E, Scherneck S. Kommunikation von Arzneimittelrisiken in der Schwangerschaft. PHARMAKON. 2020; 8(6):398-403
  • Weber-Schoendorfer C, Beck E, Dathe K. A project to improve data quality on congenital disorders after maternal medication during pregnancy – extending the follow-up period to two years [Abstract]. Reprod Toxicol. 2020; 97:2
  • Padberg S, Thumfart J, Börning SJ, Müller D, Dathe K, Schaefer C. Are patients of a large paediatric nephrology department an appropriate population to investigate long-term effects of prenatal drug exposure in a retrospective approach? [Abstract]. Reprod Toxicol. 2020; 97:3-4
  • Onken M, Schaefer C, Dathe K. Narcolepsy and pregnancy - a scoping review [Abstract]. Reprod Toxicol. 2020; 97:5-6
  • Hultzsch S, Paulus W, Padberg S, Fietz A-K, Schaefer C, Dathe K. Pregnancy outcome following first trimester exposure to naproxen: a collaborative case series from TIS Berlin and Ulm [Abstract]. Reprod Toxicol. 2020; 97:1
  • Hoeltzenbein M, Beck E, Fietz A-K, Schäfer M, Dathe K, Schaefer C. Antihypertensive treatment during pregnancy: An evaluation of the German Embryotox Database. [Abstact]. Pharmacoepidemiol Drug Saf. 2020; 29(S3):532-3
  • Schink T, Wentzell N, Dathe K, Onken M, Haug U. Estimating the Beginning of Pregnancy in German Claims Data: Development of an Algorithm With a Focus on the Expected Delivery Date. Frontiers in Public Health. 2020; 8:350
  • Rosman AN, Schaefer C, Brand T. Environment and Occupation. In: Shawe J, Steegers EAP, Verbiest S, editors. Preconception Health and Care: A Life Course Approach. Cham: Springer International Publishing; 2020. p. 237-59
  • Wagner JK, Dathe K, Schaefer C, Hoeltzenbein M. Ulipristal acetate and pregnancy outcome—an observational study. Human Reproduction. 2020; 35(4):751-8
  • Dathe K, Schaefer C. Therapie mit NSAID und Paracetamol in der Schwangerschaft. Bull Arzneimittelsicherheit. 2020;2020(1):9-14
  • Schaefer C. Ondansetron und die Krux der Risikokommunikation zu Arzneimitteln bei Schwangeren. Arzneiverordnung in der Praxis. 2020; 47(1-2):73-7
  • Stegherr R, Allignol A, Meister R, Schaefer C, Beyersmann J. Estimating cumulative incidence functions in competing risks data with dependent left-truncation. Stat Med. 2020;39(4):481-93
  • Philipps W, Fietz A-K, Meixner K, Bluhmki T, Meister R, Schaefer C, Padberg S. Pregnancy outcome after first‑trimester exposure to fosfomycin for the treatment of urinary tract infection: an observational cohort study. Infection. 2020;48(1):57-64
  • Kayser A, Beck E, Hoeltzenbein M, Zinke S, Meister R, Weber-Schoendorfer C, Schaefer C. Neonatal effects of intrauterine metoprolol/bisoprolol exposure during the second and third trimester: a cohort study with two comparison groups. Journal of Hypertension. 2020;38(2):354-61
  • Weber-Schoendorfer C, Kayser A, Tissen-Diabaté T, Winterfeld U, Eleftheriou G, Te Winkel B, Diav-Citrin O, Greenall A, Hoeltzenbein M, Schaefer C. Fetotoxic risk of AT1 blockers exceeds that of angiotensin-converting enzyme inhibitors: an observational study. Journal of Hypertension. 2020;38(1):133-41
  • Dathe K, Schaefer C. Arzneimittelbehandlung von Schwangeren. Medizin Studieren SS/2020 - Deutsches Ärzteblatt. 2020:32-5

Beiträge in Fachzeitschriften und Fachbüchern 2019

  • Dathe K, Frank J, Padberg S, Hultzsch S, Meixner K, Beck E, Meister R, Schaefer C. Negligible risk of prenatal ductus arteriosus closure or fetal renal impairment after third-trimester paracetamol use: evaluation of the German Embryotox cohort. BJOG. 2019; 126(13):1560-7
  • Dathe K, Schaefer C. Arzneimittelbehandlung der Schwangeren. Dt Aerztebl. 2019;116:783-90
  • Dathe K, Hultzsch S, Pritchard LW, Schaefer C. Risk estimation of fetal adverse effects after short-term second trimester exposure to non-steroidal anti-inflammatory drugs based on a literature review. Reproductive Toxicology. 2019;88:139
  • Weber-Schoendorfer C, Tissen-Diabaté T, Kayser A, Hoeltzenbein M, Schaefer C. Why does renin-angiotensin system inhibitor exposure happen during later pregnancy despite warnings – an approach to the problem. Reproductive Toxicology. 2019;88:129-30
  • Hoeltzenbein M, Slimi S, Fietz A-K, Onken M, Dathe K, Schaefer C. Lacosamide use during pregnancy – An evaluation of the German embryotox database. Reproductive Toxicology. 2019;88:143-4
  • Beck E, Wagner JK, Meixner K, Dathe K, Weber-Schoendorfer C. Online data acquisition using REDCap – long-term follow-up of children with intrauterine drug exposure. Reproductive Toxicology. 2019;88:130
  • Bluhmki T, Fietz A-K, Stegherr R, Beck E, Padberg S, Beyersmann J, Schaefer C, Meister R. Multistate methodology improves risk assessment under time-varying drug intake—a new view on pregnancy outcomes following coumarin exposure. Pharmacoepidemiology and Drug Safety. 2019; 28(5):616-24
  • Hoeltzenbein M, Tissen-Diabaté T, Fietz A-K, Schäfer M, Kayser A, Weber-Schoendorfer C, Beck E, Meister R, Schaefer C. Challenges in analysis of antihypertensive exposures and birth defect rates in women with chronic hypertension: an evaluation of the German Embryotox Database [Abstract]. Med Genetik. 2019;31(1):142
  • Weber-Schoendorfer C. Sicherheit von Antirheumatika in der Schwangerschaft, arthrits + rheuma - Zeitschrift für Orthopädie und Rheumatologie 2019; 39: 226-233

Beiträge in Fachzeitschriften und Fachbüchern 2018

  • Padberg S, Bührer C, Menzel J, Weikert C, Schaefer C, Abraham K. [Xenobiotics and pathogens in breast milk : A risk for the child?]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2018; 61: 960-70.
  • Wentzell N, Haug U, Schink T, Engel S, Liebentraut J, Linder R, Onken M, Schaefer C, Dathe K. [Prescribing valproate to girls and women of childbearing age in Germany: Analysis of trends based on claims data]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2018; 61: 1022-9.
  • Schaefer C. Arzneimitteltherapiesicherheit in der Schwangerschaft - eine besondere Herausforderung. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2018; 61: 1129-38.
  • Hoeltzenbein M, Tissen-Diabaté T, Fietz A-K, Schäfer M, Kayser A, Weber-Schoendorfer C, Beck E, Meister R, Schaefer C. Challenges in analysis of antihypertensive exposures and birth defect rates in women with chronic hypertension: an evaluation of the German Embryotox Database [Abstract]. Reprod Toxicol. 2018;80:134
  • Scherneck S, Schlinke N, Beck E, Grupe K, Weber-Schoendorfer C, Schaefer C. Pregnancy outcome after first-trimester exposure to metformin: a prospective cohort study. Reprod Toxicol 2018; 81: 79-83.
  • Hoeltzenbein M, Fietz A-K, Kayser A, Zinke S, Meister R, Weber-Schoendorfer C, Schaefer C. Pregnancy outcome after first trimester exposure to bisoprolol: an observational cohort study. J Hypertension 2018; 36: 2109-17.
  • Hoeltzenbein M, Tissen-Diabaté T, Fietz A-K, Zinke S, Kayser A, Meister R, Weber-Schoendorfer C, Schaefer C. Increased rate of birth defects after first trimester use of angiotensin converting enzyme inhibitors – Treatment or hypertension related? An observational cohort study. Pregnancy Hypertens 2018;13:65-71.
  • Winterfeld U, Weber-Schöndorfer C, Schaefer C, von Elm E, Buclin T. Ethical approval for multicenter cohort studies on drug exposure during pregnancy: a survey among members of the European Network of Teratology Information Services (ENTIS). Reprod Toxicol 2018; 80: 68-72.
  • Dathe K, Fietz AK, Pritchard LW, Padberg S, Hultzsch S, Meixner K, Meister R, Schaefer C. No evidence of adverse pregnancy outcome after exposure to ibuprofen in the first trimester – Evaluation of the national Embryotox cohort. Reprod Toxicol 2018;79:32-8.
  • Padberg S, Tissen-Diabate T, Dathe K, Hultzsch S, Meixner K, Linsenmeier V, Meister R, Schaefer C. Safety of diclofenac use during early pregnancy: A prospective observational cohort study. Reprod Toxicol 2018;77:122-9.
  • Dathe K, Padberg S, Hultzsch S, Kohler LM, Meixner K, Fietz AK, Tissen-Diabate T, Meister R, Schaefer C. Exposure to cox-2 inhibitors (coxibs) during the first trimester and pregnancy outcome: a prospective observational cohort study. Eur J Clin Pharmacol 2018;74:489-95.
  • Hoeltzenbein M, Tissen-Diabate T, Fietz AK, Zinke S, Kayser A, Meister R, Weber-Schoendorfer C, Schaefer C. Pregnancy outcome after first trimester use of angiotensin AT1 receptor blockers: an observational cohort study. Clin Res Cardiol 2018;107: 679-87.
  • Onken M, Mick I, Schaefer C. Paliperidone and pregnancy—an evaluation of the German Embryotox database. Arch Womens Ment Health 2018; 21: 657-62.
  • Rohde A, Hocke A, Schaefer C. Die Betreuung psychisch kranker Schwangerer. Der Gynäkologe 2018;51:86-93.
  • Dathe K, Schaefer C. Drug safety in pregnancy: the German Embryotox institute. Eur J Clin Pharmacol 2018;74:171-9.
  • Spielmann K, Kayser A, Beck E, Meister R, Schaefer C. Pregnancy outcome after anti-migraine triptan use: A prospective observational cohort study. Cephalalgia 2018;38:1081-92.

Beiträge in Fachzeitschriften und Fachbüchern 2017

  • Schaefer C. Antidepressive Therapie in der Schwangerschaft. Autismus beim Kind durch Antidepressiva? Info Neurologie & Psychiatrie. 2017;10.
  • Dathe K, Padberg S, Hultzsch S, Meixner K, Tissen-Diabate T, Meister R, Beck E, Schaefer C. Metamizole use during first trimester-A prospective observational cohort study on pregnancy outcome. Pharmacoepidemiol Drug Saf. 2017;26(10):1197-204.
  • Philipps W, Hoeltzenbein M, Grund D, Schaefer C. Fatal pregnancy outcome of a woman with idiopathic pulmonary hypertension. Reprod Toxicol. 2017;72:215-6.
  • Padberg S, Linsenmeier V, Dathe K, Hultzsch S, Meixner K, Tissen-Diabaté T, Meister R, Schaefer C. Pregnancy outcome after first trimester exposure to diclofenac: An observational cohort study from the German Embryotox Pharmacovigilance Institute. Reprod Toxicol. 2017;72:206.
  • Onken M, Schaefer C. Urinary retention in a neonate following in utero exposure to citalopram: A case report. Reprod Toxicol. 2017;72:213.
  • Mick I, Onken M, Christof S. Paliperidone exposure during pregnancy: A prospective case series from the German Embryotox database. Reprod Toxicol. 2017;72:215.
  • Hoeltzenbein M, Beck E, Fietz A-K, Wernicke J, Zinke S, Kayser A, Padberg S, Weber-Schoendorfer C, Meister R, Schaefer C. Pregnancy outcome after first trimester use of methyldopa: A prospective observational cohort study. Reprod Toxicol 2017;72:204.
  • Weber-Schoendorfer C, Beck E, Tissen-Diabate T, Schaefer C. Leflunomide - A human teratogen? A still not answered question. An evaluation of the German Embryotox pharmacovigilance database. Reprod Toxicol. 2017;71:101-7.
  • Padberg S, Mick I, Frenzel C, Greil R, Hilberath J, Schaefer C. Transient congenital dilated cardiomyopathy after maternal R-CHOP chemotherapy during pregnancy. Reprod Toxicol. 2017;71:146-9.
  • Hoeltzenbein M, Beck E, Fietz AK, Wernicke J, Zinke S, Kayser A, Padberg S, Weber-Schoendorfer C, Meister R, Schaefer C. Pregnancy Outcome After First Trimester Use of Methyldopa: A Prospective Cohort Study. Hypertension. 2017;70(1):201-8.
  • Huttel E, Padberg S, Meister R, Beck E, Schaefer C. Pregnancy outcome of first trimester exposure to the vitamin K antagonist phenprocoumon depends on duration of treatment. Thromb Haemost. 2017;117(5):870-9.
  • Richardson JL, Stephens S, Yates LM, Diav-Citrin O, Arnon J, Beghin D, Kayser A, Kennedy D, Cupitt D, Te Winkel B, Peltonen M, Kaplan YC, Thomas SH. Pregnancy outcomes after maternal varenicline use; analysis of surveillance data collected by the European Network of Teratology Information Services. Reprod Toxicol. 2017;67:26-34.
  • Beck E, Lechner A, Schaefer C. Who seeks Teratology Information Service's advice? Assessing the risk of selection bias in observational cohort studies on drug risks in pregnancy. Reprod Toxicol. 2017;67:79-84.

Beiträge in Fachzeitschriften und Fachbüchern 2016

  • Hultzsch S, Schaefer C. [Analgesic drugs during pregnancy]. Schmerz. 2016;30(6):583-93.
  • Hoeltzenbein M, Beck E, Rajwanshi R, Gotestam Skorpen C, Berber E, Schaefer C, Ostensen M. Tocilizumab use in pregnancy: Analysis of a global safety database including data from clinical trials and post-marketing data. Semin Arthritis Rheum. 2016;46(2):238-45.
  • Dathe K, Beck E, Schaefer C. Pregnancy outcome after chelation therapy in Wilson disease. Evaluation of the German Embryotox Database. Reprod Toxicol. 2016;65:39-45.
  • Hultzsch S. Schmertherapie in der Schwangerschaft. In: Eckart J, Jaeger K, Möllhoff T, editors. Anästhesiologie Kompendium und Repetitorium zur interdisziplinären Weiter- und Fortbildung. ecomed Medizin. 49. Aktualisierung 09/2016 ed. Landsberg: ecomed; 2016.
  • Kayser A, Schaefer C. Medikamentöse Therapie bei Schwangerschaft oder Kinderwunsch. Gynäkologische Endokrinologie 2016;15:53-64.Diav-Citrin O, Shechtman S, Arnon J, Wajnberg R, Borisch C, Beck E, Richardson JL, Bozzo P, Nulman I, Ornoy A. Methylphenidate in Pregnancy: A Multicenter, Prospective, Comparative, Observational Study. J Clin Psychiatry. 2016;77(9):1176-81.
  • Hoeltzenbein M, Beck E, Rajwanshi R, Skorpen CG, Berber E, Schaefer C, Östensen M. Tocilizumab Use in Pregnancy: Analysis of a Global Safety Database Including Data from Clinical Trials and Post-Marketing Data. Pharmacoepidemiology and Drug Safety. 2016;25(Suppl 3):323.
  • Douros A, Schaefer C, Kreutz R, Garbe E. [Pharmacovigilance in Germany : It is about time]. Internist (Berl). 2016;57(6):616-23.
  • Gotestam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, da Silva J, Nelson-Piercy C, Cetin I, Costedoat-Chalumeau N, Dolhain R, Forger F, Khamashta M, Ruiz-Irastorza G, Zink A, Vencovsky J, Cutolo M, Caeyers N, Zumbuhl C, Ostensen M. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75(5):795-810.
  • Weber-Schoendorfer C, Schaefer C. Pregnancy outcome after tocilizumab therapy in early pregnancy-a case series from the German Embryotox Pharmacovigilance Center. Reprod Toxicol. 2016;60:29-32.
  • Weber-Schoendorfer C, Beck E, Schaefer C. Pregnancy outcomes in women who have taken leflunomide before or during pregnancy – A prospective case series from the German Embryotox center. Reprod Toxicol. 2016;60:186.
  • Hüttel E, Beck E, Meister R, Schaefer C. Risk increase of spontaneous abortion associated with maternal phenprocoumon therapy depends on time of treatment discontinuation during first trimester. Reprod Toxicol. 2016;60:174.
  • Hoeltzenbein M, Beck E, Rajwanshi R, Skorpen CG, Berber E, Schaefer C, Østensen M. Tocilizumab use in pregnancy: Analysis of a Global Safety Database including data from clinical trials and post-marketing data. Reprod Toxicol. 2016;60:173.
  • Berard A, Wisner KL, Hultzsch S, Chambers C. Field studies versus database studies on the risks and benefits of medication use during pregnancy: Distinct pieces of the same puzzle. Reprod Toxicol. 2016;60:123-8.
  • Beck E, Lechner A, Schaefer C. Who seeks teratology information service's advice? A Germany-based evaluation of representativeness by socioeconomic indicators (Abstract). Reprod Toxicol. 2016;60:172-3.
  • Hoeltzenbein M, Beck E, Meixner K, Schaefer C, Kreutz R. Pregnancy outcome after exposure to the novel oral anticoagulant rivaroxaban in women at suspected risk for thromboembolic events: a case series from the German Embryotox Pharmacovigilance Centre. Clinical research in cardiology: official journal of the German Cardiac Society. 2016;105(2):117-26.

Beiträge in Fachzeitschriften und Fachbüchern 2015

  • Scherneck S, Schopa FL, Entezami M, Kayser A, Weber-Schoendorfer C, Schaefer C. Reversible oligohydramnios in the second trimester of pregnancy in two patients with long-term diclofenac exposure. Reprod Toxicol. 2015;58:61-4.
  • Nijhof S, Kutz PI, Schulze R, Schaefer C, Menke T, Roll C. [Congenital Intermittent Third-degree Atrioventricular Block Associated with Retinoid Exposure in Pregnancy]. Z Geburtshilfe Neonatol. 2015;219(06):289-92.
  • Rohde A, Dorsch V, Schaefer C. Psychische Störung und Elternschaft. In: Rohde A, Dorsch V, Schaefer C, editors. Psychopharmakotherapie in Schwangerschaft und Stillzeit. 4., vollständig überarbeitete und erweiterte Auflage ed2015.
  • Solecki R, Rauch M, Gall A, Buschmann J, Clark R, Fuchs A, Kan H, Heinrich V, Kellner R, Knudsen TB, Li W, Makris SL, Ooshima Y, Paumgartten F, Piersma AH, Schonfelder G, Oelgeschlager M, Schaefer C, Shiota K, Ulbrich B, Ding X, Chahoud I. Continuing harmonization of terminology and innovations for methodologies in developmental toxicology: Report of the 8th Berlin Workshop on Developmental Toxicity, 14-16 May 2014. Reprod Toxicol. 2015;57:140-6.
  • Weber-Schoendorfer C, Oppermann M, Wacker E, Bernard N, network of French pharmacovigilance c, Beghin D, Cuppers-Maarschalkerweerd B, Richardson JL, Rothuizen LE, Pistelli A, Malm H, Eleftheriou G, Kennedy D, Kadioglu Duman M, Meister R, Schaefer C. Pregnancy outcome after TNF-alpha inhibitor therapy during the first trimester: a prospective multicentre cohort study. Br J Clin Pharmacol. 2015;80(4):727-39.
  • Weber-Schoendorfer C, Oppermann M, Wacker E, Bernard N, network of French pharmacovigilance c, Beghin D, Cuppers-Maarschalkerweerd B, Richardson JL, Rothuizen LE, Pistelli A, Malm H, Eleftheriou G, Kennedy D, Kadioglu Duman M, Meister R, Schaefer C, (ENTIS) TENoTIS. Pregnancy outcomes and infant's development after maternal TNF-alpha inhibitor in pregnancy-Design of an observational multicenter cohort study. Br J Clin Pharmacol. 2015;80(4):727-39.
  • Schaefer C. Embryotox und das Dilemma mit Medikamenten in der Schwangerschaft. In: Rohde A, GmbH PV, editors. Frauen-Leid und Frauen-Stärkung Im Fokus von Gynäkologischer Psychosomatik und Gynäkopsychiatrie. Forschung fuer die Praxis - Hochschulschriften. Köln: Psychiatrie Verlag; 2015.
  • Paulzen M, Grunder G, Orlikowsky T, Graf CM, Hoeltzenbein M, Veselinovic T. Suicide attempt during late pregnancy with quetiapine: nonfatal outcome despite severe intoxication. J Clin Psychopharmacol. 2015;35(3):343-4.
  • Oppermann M, Borisch C, Schaefer C. Hip arthroplasty with high chromium and cobalt blood levels--Case report of a patient followed during pregnancy and lactation period. Reprod Toxicol. 2015;53:51-3.
  • Wacker E, Navarro A, Meister R, Padberg S, Weber-Schoendorfer C, Schaefer C. Does the average drug exposure in pregnant women affect pregnancy outcome? A comparison of two approaches to estimate the baseline risks of adverse pregnancy outcome. Pharmacoepidemiol Drug Saf. 2015;24(4):353-60.
  • Oppermann M, Schaefer C. Fetotoxisches Risiko der AT1-Antagonisten and ACE-Hemmer. Bulletin zur Arzneimittelsicherheit Informationen and BfArM und PEI. 2015;2015(1):8-11.

Beiträge in Fachzeitschriften und Fachbüchern 2014

  • Padberg S, Wacker E, Meister R, Panse M, Weber-Schoendorfer C, Oppermann M, Schaefer C. Observational Cohort Study of Pregnancy Outcome after First-Trimester Exposure to Fluoroquinolones. Antimicrob Agents Chemother. 2014;58(8):4392-8.
  • Weber-Schoendorfer C, Wacker E, Schaefer C. Pregnancy Outcome after Dimethyl Fumarate Treatment during Early Pregnancy. A Prospective Case Series (Abstract). Birth Defects Research Part A: Clinical and Molecular Teratology. 2014;100(7):531.
  • Bernard N, Beghin D, Huettel E, Dunstan H, Ieri A, te winkel B, Jonville-Bera A-P, Damase-Michel C, Vial T, Pharmacovigilance NF. Pregnancy Outcome after In Utero Exposure to Baclofen: An ENTIS Collaborative Study. Birth Defects Research Part A Clinical and Molecular Teratology. 2014;100(7):525-.
  • Tummler G, Rissmann A, Meister R, Schaefer C. Congenital bladder exstrophy associated with Duogynon hormonal pregnancy tests-signal for teratogenicity or consumer report bias? Reprod Toxicol. 2014;45:14-9.
  • Weber-Schoendorfer C, Chambers C, Wacker E, Beghin D, Bernard N, Network of French Pharmacovigilance C, Shechtman S, Johnson D, Cuppers-Maarschalkerweerd B, Pistelli A, Clementi M, Winterfeld U, Eleftheriou G, Pupco A, Kao K, Malm H, Elefant E, Koren G, Vial T, Ornoy A, Meister R, Schaefer C. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study. Arthritis Rheumatol. 2014;66(5):1101-10.
  • Weber-Schoendorfer C, Hoeltzenbein M, Wacker E, Meister R, Schaefer C. No evidence for an increased risk of adverse pregnancy outcome after paternal low-dose methotrexate: an observational cohort study. Rheumatology (Oxford). 2014;53(4):757-63.
  • Hoeltzenbein M, Scherneck S, Wacker E, Salzmann E, Juch H, Schaefer C. Genetics in disguise - role of pharmacogenetics in the fetal anticonvulsant syndrome (Abstract). medizinische genetik. 2014;26(1):141.
  • Schaefer C, Weber-Schoendorfer C. Problematische Arzneimittel in der Schwangerschaft und Stillzeit. Internist Prax. 2014;54:197-208.
  • Schaefer C. Medikamentöse Therapie in Schwangerschaft und Stillzeit. Klinikarzt. 2014;43(9):412-8.
  • Schaefer C. Therapie während der Schwangerschaft und Stillzeit. In: Kallinich T, Wittkowski H, editors. Familiäres Mittelmeerfieber. Bremen: Uni-Med Bremen; 2014. p. 132-3.

Beiträge in Fachzeitschriften und Fachbüchern 2013

  • Dostal M, Weber-Schoendorfer C, Sobesky J, Schaefer C. Pregnancy outcome following use of levodopa, pramipexole, ropinirole, and rotigotine for restless legs syndrome during pregnancy: a case series. Eur J Neurol. 2013;20(9):1241-6.
  • Habermann F, Fritzsche J, Fuhlbruck F, Wacker E, Allignol A, Weber-Schoendorfer C, Meister R, Schaefer C. Atypical antipsychotic drugs and pregnancy outcome: a prospective, cohort study. J Clin Psychopharmacol. 2013;33(4):453-62.
  • Hoeltzenbein M, Stieler K, Panse M, Wacker E, Schaefer C. Allopurinol Use during Pregnancy - Outcome of 31 Prospectively Ascertained Cases and a Phenotype Possibly Indicative for Teratogenicity. PLoS One. 2013;8(6):e66637.
  • Weber-Schoendorfer C, Oppermann M, Schaefer C. Pregnancy outcomes and infant‘s development after maternal TNF-alpha inhibitor therapy in pregnancy – Design of an observational multicenter cohort study (Abstract). Reprod Toxicol. 2013;37:86.
  • Hoeltzenbein M, Stieler K, Panse M, Wacker E, Schaefer C. First trimester use of allopurinol – Outcome of 31 prospectively ascertained pregnancies and a phenotype possibly indicative for teratogenicity (Abstract). Reprod Toxicol. 2013;37.
  • Schaefer C. Arzneimittelprojekt Embryotox: Sicherheit für Mutter und Kind. Dtsch Arztebl International. 2013;110(21):1048.
  • Oppermann M, Padberg S, Kayser A, Weber-Schoendorfer C, Schaefer C. Angiotensin-II-receptor-1-antagonist fetopathy - Risk assessment, critical time period, and vena cava thrombosis as a possible new feature. Br J Clin Pharmacol. 2013;75(3):822-30.
  • Wacker E, Schaefer C, Meister R. No chance for bias - Methodological considerations for drug risk assesment in pregnancy (Abstract). Reprod Toxicol. 2013;37:85-6.
  • Padberg S, Schaefer C. Antiinfektiva während der Schwangerschaft und im Wochenbett. In: Friese K, Mylonas I, Schulze A, editors. Infektionserkrankungen der Schwangeren und des Neugeborenen. Berlin Heidelberg: Springer; 2013. p. 111-25.

Beiträge in Fachzeitschriften und Fachbüchern 2012

  • Tümmler G, Schaefer C. Duogynon: Angeborene Fehlbildungen nach Applikation der Östrogen-Progesteron-Kombination in der Schwangerschaft – Auswertung einer retrospektiven Fallserie Bulletin zur Arzneimittelsicherheit Informationen and BfArM und PEI. 2012;2012(4):20-3.
  • Panchaud A, Csajka C, Merlob P, Schaefer C, Berlin M, De SM, Vial T, Ieri A, Malm H, Eleftheriou G, Stahl B, Rousso P, Winterfeld U, Rothuizen LE, Buclin T. Pregnancy outcome following exposure to topical retinoids: a multicenter prospective study. J Clin Pharmacol. 2012;52(12):1844-51.
  • Artmann T, Hönig A, Wirbelauer J, Schaefer C, Schelling P, Kranke P. Stillen nach Narkosen: Ist eine Stillpause obligat? Geburtshilfe Frauenheilkd. 2012;72(11):983-7.
  • Hoeltzenbein M, Weber-Schoendorfer C, Borisch C, Allignol A, Meister R, Schaefer C. Pregnancy outcome after paternal exposure to azathioprine/6-mercaptopurine. Reprod Toxicol. 2012;34(3):364-9.
  • Schaefer C. Paradigm change in pain therapy: Do we take leave of paracetamol in pregnancy? Reprod Toxicol. 2012;34(2):150.
  • Fritzsche J, Pilch A, Mury D, Schaefer C, Weber-Schoendorfer C. Infliximab and Adalimumab Use During Breastfeeding. Journal of Clinical Gastroenterology. 2012;46(8):718-9.
  • Borisch C, Kayser A, Weber-Schoendorfer C, Schaefer C. Severe neutropenia in a newborn after clozapine therapy during pregnancy. Reprod Toxicol. 2012;34(2):158.
  • Schaefer C. Allgemeine Gynäkologie. Arzneimittelsicherheit in der Schwangerschaft – eine Utopie? Geburtshilfe Frauenheilkd. 2012;72(8):701-2.
  • Schaefer C, Weber-Schoendorfer C. Aktuelle Aspekte zum Arzneimitteleinsatz in Schwangerschaft und Stillzeit. Krankenhauspharmazie. 2012;33(8):347-55.
  • Fritzsche J, Borisch C, Schaefer C. Case Report: High Chromium and Cobalt Levels in a Pregnant Patient with Bilateral Metal-on-Metal Hip Arthroplasties. Clin Orthop Relat Res. 2012;470(8):2325-31.
  • Bar-Oz B, Weber-Schoendorfer C, Berlin M, Clementi M, Di Gianantonio E, de Vries L, De Santis M, Merlob P, Stahl B, Eleftheriou G, Manakova E, Hubickova-Heringova L, Youngster I, Berkovitch M. The outcomes of pregnancy in women exposed to the new macrolides in the first trimester: a prospective, multicentre, observational study. Drug Saf. 2012;35(7):589-98.
  • Oppermann M, Fritzsche J, Weber-Schoendorfer C, Keller-Stanislawski B, Allignol A, Meister R, Schaefer C. A(H1N1)v2009: a controlled observational prospective cohort study on vaccine safety in pregnancy. Vaccine. 2012;30(30):4445-52.
  • Rohde A, Dorsch VM, Schaefer C. [Treatment with psychopharmaca during pregnancy - part I: as little as possible but as much as necessary]. Fortschr Neurol Psychiatr. 2012;80(4):227-40.
  • Schaefer C, Hoffmann-Walbeck P. [Poisonings in pregnancy]. Med Klin Intensivmed Notfmed. 2012;107(2):118-22.
  • Hoeltzenbein M, Elefant E, Vial T, Finkel-Pekarsky V, Stephens S, Clementi M, Allignol A, Weber-Schoendorfer C, Schaefer C. Teratogenicity of mycophenolate confirmed in a prospective study of the European Network of Teratology Information Services. Am J Med Genet A. 2012;158A(3):588-96.
  • Schaefer C, Weber-Schoendorfer C. Aktuelle Aspekte zum Arzneimitteleinsatz in Schwangerschaft und Stillzeit. Arzneimitteltherapie. 2012;30(12):383-3090.
  • Schaefer C, Oppermann M, Wacker E, Weber-Schoendorfer C. [Drug safety in pregnancy - the Embryotox project]. Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen. 2012;106(10):723-8.
  • Schaefer C. Grundsätzliches zur Arzneimitteltherapie in der Schwangerschaft. In: Schaefer C, Spielmann H, Weber-Schöndorfer C, Vetter K, editors. Arzneimittel in Schwangerschaft und Stillzeit. 8 ed. München: Urban & Fischer in Elsevier; 2012. p. 3-31.
  • Reuvers N, Vial T, Schaefer C, Elefant E, de Santis M, Malm H, Wentges-van HN. Pregnancy Outcome after First Trimester Exposure to Malarone (Atovaquone-Proguanil): A Prospective Case-Series [Abstract]. Birth Defects Research (Part A). 2012;94(5):329.
  • Schaefer C, Spielmann H, Vetter K, Weber-Schöndorfer C. Arzneimittel in Schwangerschaft und Stillzeit: Elsevier, Urban & Fischer; 2012.

Beiträge in Fachzeitschriften und Fachbüchern 2011

  • Kranke P, Frambach T, Schelling P, Wirbelauer J, Schaefer C, Stamer U. [Anaesthesia and breast-feeding: should breast-feeding be discouraged?]. Anasthesiol Intensivmed Notfallmed Schmerzther. 2011;46(5):304-11.
  • Regitz-Zagrosek V, Seeland U, Geibel-Zehender A, Gohlke-Barwolf C, Kruck I, Schaefer C. Cardiovascular diseases in pregnancy. Dtsch Arztebl Int. 2011;108(16):267-73.
  • Schaefer C. Drug safety in pregnancy: utopia or achievable prospect? Risk information, risk research and advocacy in Teratology Information Services. Congenit Anom. 2011;51(1):6-11.
  • Weber-Schoendorfer C, Fritzsche J, Schaefer C. Pregnancy outcomes in women exposed to adalimumab or infliximab: The experience of the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy (Abstract). Reprod Toxicol. 2011;31(2):267-8.
  • Schaefer C. Sartane und ACE-Hemmer schaden dem Feten. Frauenarzt. 2011;52(2):122-3.
  • Oppermann M, Padberg S, Schaefer C. Angiotensin II-receptor 1-antagonists during 2nd or 3rd trimester: Evaluation of a case series from the Berlin Institute for Clinical Teratolog and Drug Risk Assessment in Pregnancy (Abstract). Reprod Toxicol. 2011;31(2):264.
  • Hultzsch S, Weber-Schoendorfer C, Schaefer C. Pregnancy outcomes after exposure to etanercept (Abstract). Reprod Toxicol. 2011;31(2):260.
  • Hoeltzenbein M, Supcun-Ritzler S, Langthaler M, Daumer-Haas C, Schaefer C. Lacosamide during pregnancy: Experience of the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy (Abstract). Reprod Toxicol. 2011;31(2):259.
  • Fritzsche J, Mury D, Wintgens KF, Pilch A, Schäfer C, Weber-Schoendorfer C. Infliximab and adalimumab use during lactation (Abstract). Reprod Toxicol. 2011;31(2):258.
  • Henze T, Janzen RWC, Schumm F, Melms A, Sieb JP, Köhler W, Heidenreich F, Tackenberg B, Weber-Schoendorfer C. Immuntherapie bei Myasthenia gravis und Lambert-Eaton-Syndrom. Akt Neurol. 2010;37(10):505-17.
  • Schaefer C, Wieacker P. Teratogene Faktoren. In: Murken J-D, Grimm T, Holinski-Feder E, Zerres K, editors. Taschenlehrbuch Humangenetik. 8. Aufl. ed. Stuttgart: Thieme; 2011. p. 437-58.
  • Schaefer C, Rohde A. Psychopharmakotherapie und psychiatrische Begleitung in Schwangerschaft und Stillzeit. In: Möller H-J, Laux G, Kapfhammer H-P, editors. Psychiatrie, Psychosomatik, Psychotherapie. 2. 4. Aufl. ed. Berlin Heidelberg: Springer; 2011. p. 1429-42.

Beiträge in Fachzeitschriften und Fachbüchern 2010

  • Schaefer C. Pädiatrie aktuell: Risiken der Sartantherapie in der Schwangerschaft. Monatsschrift Kinderheilkunde. 2010;158(12):1201.
  • Hoeltzenbein M, Weber-Schoendorfer C, Padberg S, Borisch C, Schaefer C. Paternal exposure to azathioprine/6-mercaptopurine—Experience of Berlin TIS [Abstract]. Reprod Toxicol. 2010;30(2):238-9.
  • Schaefer C, Fritzsche J, Karbaum F, Meister R, Weber-Schoendorfer C. 2009 H1N1 vaccination in pregnancy-experience of the European network of teratology information services (ENTIS). Reprod Toxicol. 2010;30(2):220.
  • Hoeltzenbein M, Elefant E, Garayt C, Ornoy A, Clementi M, Manakova E, Merlob P, Rodriguez-Pinilla E, Rothuizen L, Smorlesi C, Bernke te Winkel, de Santis M, Stephens S, Vial T, Weber-Schoendorfer C, Schaefer C. Maternal exposure to mycophenolate mofetil in pregnancy-results of the ENTIS collaborative study [Abstract]. Reprod Toxicol. 2010;30(2):228.
  • Habermann F, Karbaum F, Meister R, Weber-Schoendorfer C, Schaefer C. Pregnancy outcome after exposure to second-generation antispychotics [Abstract]. Reprod Toxicol. 2010;30(2):228.
  • Fritzsche J, Borisch C, Weber-Schoendorfer C, Schaefer C. High levels of chromium and cobalt in pregnant patient with metal-om-metal hip arthroplasty [Abstract]. Reprod Toxicol. 2010;30(2):237-8.
  • Dostal M, Felberg M, Weber-Schoendorfer C, Schaefer C. Treatment of restless legs syndrome during pregnancy [Abstract]. Reprod Toxicol. 2010;30(2):236-7.
  • Hoyer AC, Henrich W, Schaefer C, Spors B, Czernik C. Coumarin embryopathy after intrauterine exposure to vitamin K antagonists within the first 10 postmenstrual weeks. Ultraschall Med. 2010;31(4):411-3.
  • Nickerson ML, Kostiha BN, Brandt W, Fredericks W, Xu KP, Yu FS, Gold B, Chodosh J, Goldberg M, Lu dW, Yamada M, Tervo TM, Grutzmacher R, Croasdale C, Hoeltzenbein M, Sutphin J, Malkowicz SB, Wessjohann L, Kruth HS, Dean M, Weiss JS. UBIAD1Mutation Alters a Mitochondrial Prenyltransferase to Cause Schnyder Corneal Dystrophy. PLoS One. 2010;5(5):e10760.
  • Chen W, Ullmann R, Langnick C, Menzel C, Wotschofsky Z, Hu H, Doring A, Hu Y, Kang H, Tzschach A, Hoeltzenbein M, Neitzel H, Markus S, Wiedersberg E, Kistner G, van Ravenswaaij-Arts CM, Kleefstra T, Kalscheuer VM, Ropers HH. Breakpoint analysis of balanced chromosome rearrangements by next-generation paired-end sequencing. Eur J Hum Genet. 2010;18(5):539-43.
  • Schaefer C, Meister R, Weber-Schoendorfer C. Isotretinoin exposure and pregnancy outcome: an observational study of the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy. Arch Gynecol Obstet. 2010;281(2):221-7.
  • Henze T, Janzen RWC, Schumm F, Melms A, Sieb JP, Köhler W, Heidenreich F, Tackenberg B, Weber-Schoendorfer C. Immuntherapie bei Myasthenia gravis und Lambert-Eaton-Syndrom. Akt Neurol. 2010;37(10):505-17.
  • Rabe T, Ludwig M, Goeckenjan M, Schaefer C. Was bei Langzeitkontrazeption post partum zu beachten ist. gyne – Aktuelles aus Gynäkologie und Geburtshilfe. 2010;2010(1):19-22.

Beiträge in Fachzeitschriften und Fachbüchern 2009

  • Weber-Schoendorfer C, Schaefer C. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. Multiple Sclerosis. 2009;15(9):1037-42.
  • Schaefer C, Meister R, Wentzeck R, Weber-Schoendorfer C. Fetal outcome after technetium scintigraphy in early pregnancy. Reprod Toxicol. 2009;28(2):161-6.
  • Gueneau L, Bertrand AT, Jais JP, Salih MA, Stojkovic T, Wehnert M, Hoeltzenbein M, Spuler S, Saitoh S, Verschueren A, Tranchant C, Beuvin M, Lacene E, Romero NB, Heath S, Zelenika D, Voit T, Eymard B, Ben YR, Bonne G. Mutations of the FHL1 gene cause Emery-Dreifuss muscular dystrophy. Am J Hum Genet. 2009;85(3):338-53.
  • Tzschach A, Ramel C, Kron A, Seipel B, Wuster C, Cordes U, Liehr T, Hoeltzenbein M, Menzel C, Ropers HH, Ullmann R, Kalscheuer V, Decker J, Steinberger D. Hypergonadotropic hypogonadism in a patient with inv ins (2;4). Int J Androl. 2009;32(3):226-30.
  • Schaefer C. Topische und systemische Therapie in der Schwangerschaft (Abstract). JDDG. 2009;7(Supplement 4):43.
  • Neumann TE, Allanson J, Kavamura I, Kerr B, Neri G, Noonan J, Cordeddu V, Gibson K, Tzschach A, Kruger G, Hoeltzenbein M, Goecke TO, Kehl HG, Albrecht B, Luczak K, Sasiadek MM, Musante L, Laurie R, Peters H, Tartaglia M, Zenker M, Kalscheuer V. Multiple giant cell lesions in patients with Noonan syndrome and cardio-facio-cutaneous syndrome. Eur J Hum Genet. 2009;17(4):420-5.
  • Jurgens TP, Schaefer C, May A. Treatment of cluster headache in pregnancy and lactation. Cephalalgia. 2009;29(4):391-400.
  • Hoeltzenbein M, Weber-Schoendorfer C, Schaefer C. Mycophenolate mofetil – a teratogenic drug? Experience of the Berlin Instiute of Clinical Teratology and drug risk assessment during pregnancy. Medizinische Genetik. 2009;21(1):78-9.
  • Schaefer C, Weber-Schoendorfer C. Pharmakotherapie in der Schwangerschaft. Internist. 2009;50:455-66.
  • Schaefer C, Rohde A. So wenig wie möglich, soviel wie nötig. Ärztliche Praxis Neurologie Psychiatrie. 2009;2009(11):24-7.
  • Rabe T, Ludwig M, Goeckenjan M, Schaefer C. Welche Verhütung ist im Anschluss an eine Geburt und in der Stillzeit effektiv? gyne – Aktuelles aus Gynäkologie und Geburtshilfe. 2009;2009(8):19-21.
  • Rabe T, Ludwig M, Goeckenjan M, Schaefer C. Methoden der Kontrazeption im Wochenbett und Anwendungseinschränkungen bei stillenden Frauen. gyne – Aktuelles aus Gynäkologie und Geburtshilfe. 2009;2009(12):19-23.
  • Becker CD, Stichtenoth DO, Wichmann MG, Schaefer C, Szinicz L. Blood Donors on Medication - an Approach to Minimize Drug Burden for Recipients of Blood Products and to Limit Deferral of Donors. Transfus Med Hemother. 2009;36(2):107-13.
  • Schaefer C. Arzneitherapie in Schwangerschaft und Stillzeit. In: Ärzteschaft Add, editor. Arzneiverordnungen Empfehlungen zur rationalen Pharmakotherapie. 22. Aufl. ed. Neu-Isenburg: MMI - Medizinische Medien Informations GmbH; 2009. p. 1333-45.
  • Schaefer C. Arzneimittel in der Schwangerschaft und Stillperiode. In: Reiss M, editor. Facharztwissen HNO-Heilkunde. Berlin Heidelberg: Springer; 2009. p. 1099-103.

Beiträge in Fachzeitschriften und Fachbüchern 2008

  • Panchaud A, Stahl B, Schaefer C, Berlin M, De Santis M, Vial T, Ieri A, Malm H, Eleftheriou G, Buclin T. Topical Retinoids Exposure during the First Trimester of Pregnancy. Can J Clin Pharmacol. 2008;15(3):e677-e8.
  • Diav-Citrin O, Shechtman S, Weinbaum D, Wajnberg R, Avgil M, Di GE, Clementi M, Weber-Schoendorfer C, Schaefer C, Ornoy A. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol. 2008;66(5):695-705.
  • Weber-Schoendorfer C, Schaefer C. Monoclonal antibody therapy during pregnancy-experience of the Berlin teratology information service (Abstract). Reprod Toxicol. 2008;26(1):75-6.
  • Weber-Schoendorfer C, Schaefer C. The safety of cetirizine during pregnancy a prospective observational cohort study (Abstract). Reprod Toxicol. 2008;26(1):19-23.
  • Weber-Schoendorfer C, Hannemann D, Meister R, Elefant E, Cuppers-Maarschalkerweerd B, Arnon J, Vial T, Rodriguez-Pinilla E, Clementi M, Robert-Gnansia E, De Santis M, Malm H, Dolivo A, Schaefer C. The safety of calcium channel blockers during pregnancy: a prospective, multicenter, observational study. Reprod Toxicol. 2008;26(1):24-30.
  • Schaefer C, Ornoy A, Clementi M, Meister R, Weber-Schoendorfer C. Using observational cohort data for studying drug effects on pregnancy outcome--methodological considerations. Reprod Toxicol. 2008;26(1):36-41.
  • Padberg S, Weber-Schoendorfer C, Schaefer C. Lamotrigine during lactation (Abstract). Reprod Toxicol. 2008;26(1):70-1.
  • Meister R, Schaefer C. Statistical methods for estimating the probability of spontaneous abortion in observational studies--analyzing pregnancies exposed to coumarin derivatives. Reprod Toxicol. 2008;26(1):31-5.
  • Hoeltzenbein M, Weber-Schoendorfer C, von Stackelberg L, Schaefer C. Paternal exposure to drugs—Is there an increased risk for congenital abnormalities?: Experience of the Berlin Institute for Clinical Teratology and Drug Risk Assessment during Pregnancy (Abstract). Reprod Toxicol. 2008;26(1):64.
  • Schaefer C. 50 Jahre nach Contergan - wie steht es um die Arzneimittelsicherheit in der Schwangerschaft heute? Arzneiverordnung in der Praxis. 2008;35(4):65-6.
  • Weber-Schoendorfer C, Schaefer C. Multiple sclerosis – effects of immunomodulatory therapy on pregnancy outcome: An observational study of the Teratology Information Service Berlin, Germany (Abstract). Birth Defects Research Part A: Clinical and Molecular Teratology. 2008;82(5):298.
  • Moller RS, Kubart S, Hoeltzenbein M, Heye B, Vogel I, Hansen CP, Menzel C, Ullmann R, Tommerup N, Ropers HH, Tumer Z, Kalscheuer VM. Truncation of the Down syndrome candidate gene DYRK1A in two unrelated patients with microcephaly. Am J Hum Genet. 2008;82(5):1165-70.
  • Weber-Schoendorfer C, Schaefer C. Trastuzumb exposure during pregnancy. Reprod Toxicol. 2008;25(3):390-1.
  • Hoeltzenbein M, Weber-Schoendorfer C, Von SL. Paternal exposure to drugs – Is there an increased risk for congenital abnormalities? Experience of the Berlin Institute of clinical teratology and drug risk assessment during pregnancy (Poster). Med Genetik. 2008;20(1):166.
  • Rabe T, Ludwig M, Bitzer J, Schaefer C. Schwangerschaften unter verschiedenen kontrazeptiven Methoden. J Reproduktionsmed Endokrinol. 2008;5(3):138-46.
  • Rabe T, Ludwig M, Bitzer J, Geisthövel F, Schaefer C. Terato- bzw. Mutagenität von Arzneimitteln: Wenn unter Anwendung von Kontrazeptiva eine Schwangerschaft eintritt. gyne – Aktuelles aus Gynäkologie und Geburtshilfe. 2008;2008(5):1-8.
  • Rohde A, Schaefer C. Betreuung schwangerer und stillender Patientinnen – Psychopharmakotherapie und psychiatrische Begleitung. In: Möller H-J, Laux G, Kapfhammer H-P, editors. Psychiatrie und Psychotherapie. 2. 3. Aufl. ed. Berlin
  • Heidelberg: Springer; 2008. p. 1235-44.

Beiträge in Fachzeitschriften und Fachbüchern 2007

  • Goldstein LH, Dolinsky G, Greenberg R, Schaefer C, Cohen-Kerem R, Diav-Citrin O, Malm H, Reuvers-Lodewijks ME, MM RvT-vD, Arnon J, Ornoy A, Clementi M, Di GE, Koren G, Braunstein R, Berkovitch M. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res A Clin Mol Teratol. 2007;79(10):696-701.
  • Meister R, Schaefer C. Spontaneous abortion rates: unbiased statistical estimation-with coumarins as an example [Abstract]. Reprod Toxicol. 2007;24(1):64.
  • Kallinich T, Haffner D, Niehues T, Huss K, Lainka E, Neudorf U, Schaefer C, Stojanov S, Timmann C, Keitzer R, Ozdogan H, Ozen S. Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics. 2007;119(2):e474-e783.
  • Schaefer C. Off-label-use von Medikamenten in der Schwangerschaft. Frauenarzt. 2007;48(1):20-5.

Beiträge in Fachzeitschriften und Fachbüchern 2006 und älter (Auswahl)

  • Schmitz B, Krämer G, Helmstädter C, Jokeit H, Koch S, Luef G, Schaefer C. Neuropsychologisches Outcome nach intrauteriner Valproat-Exposition. Der Nervenarzt. 2006;77(8):901-11.
  • Schaefer C. Exposure to vitamin K antagonists during pregnancy. Clin Adv Hematol Oncol. 2006;4(7):509-10.
  • Schaefer C, Hannemann D, Meister R, Elefant E, Paulus W, Vial T, Reuvers M, Robert-Gnansia E, Arnon J, De SM, Clementi M, Rodriguez-Pinilla E, Dolivo A, Merlob P. Vitamin K antagonists and pregnancy outcome. A multi-centre prospective study. Thromb Haemost. 2006;95(6):949-57.
  • Schaefer C. ACE-Hemmer im 1. Trimenon der Schwangerschaft. Der Arzneimittelbrief. 2006;40:87-8.
  • Schaefer C. Arzneimittelrisiken in der Schwangerschaft und Stillzeit. Deutsche Hebammen Zeitschrift. 2006 2006:57-8.
  • Schmitz B, Schaefer C, Pfennig A. Women and lithium treatment. In: Bauer M, Grof P, Muller-Oerlinghausen B, editors. Lithium in Neuropsychiatry. 1. Aufl. ed. London: CRC Press; 2006.
  • Kashiwagi M, Schäfer C, Kästner R, Vetter K, Abou-Dakn M. Opiatabhängigkeit und Stillen - Literaturübersicht und Empfehlungen. Geburtshilfe Frauenheilkd. 2005;65(10):938-41.
  • Schaefer C, Hannemann D, Meister R. Post-marketing surveillance system for drugs in pregnancy--15 years experience of ENTIS. Reprod Toxicol. 2005;20(3):331-43.
  • Garbis H, Elefant E, Diav-Citrin O, Mastroiacovo P, Schaefer C, Vial T, Clementi M, Valti E, McElhatton P, Smorlesi C, Rodriguez EP, Robert-Gnansia E, Merlob P, Peiker G, Pexieder T, Schueler L, Ritvanen A, Mathieu-Nolf M. Pregnancy outcome after exposure to ranitidine and other H2-blockers. A collaborative study of the European Network of Teratology Information Services. Reprod Toxicol. 2005;19(4):453-8.
  • Diav-Citrin O, Shechtman S, Ornoy S, Arnon J, Schaefer C, Garbis H, Clementi M, Ornoy A. Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study. J Clin Psychiatry. 2005;66(3):317-22.
  • Diav-Citrin O, Arnon J, Shechtman S, Schaefer C, van Tonningen MR, Clementi M, De SM, Robert-Gnansia E, Valti E, Malm H, Ornoy A. The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study. Aliment Pharmacol Ther. 2005;21(3):269-75.
  • Schaefer C. [Abnormalities in organogenesis caused by drugs with teratogenic potential]. Der Gynaekologe. 2005;38(1):16-24.
  • Schaefer C. Umweltbedingte vorgeburtliche Entwicklungsschäden. In: Ganten D, Ruckpaul K, R.R. W, editors. Molekularmedizinische Grundlagen von fetalen und neonatalen Erkrankungen. Molekulare Medizin. 1. Aufl. ed. Berlin Heidelberg: Springer; 2005. p. 231-64.
  • Schaefer C. Are new antikonvulsants safer than classical? [Abstract]. Reprod Toxicol. 2004;19(2):247.
  • Schaefer C. Major birth defects and classifical anticonvulsants-how to resume the risk [Abstract]. Reprod Toxicol. 2004;19(2):244-5.
  • Schaefer C. Angiotensin II-receptor-antagonists: further evidence of fetotoxicity but not teratogenicity. Birth Defects Research (Part A). 2003;67(8):591-4.
  • Schaefer C, Kudicke S. Fetotoxizitaet von Angiotensin-II- (AT-II) Rezeptor-Antagonisten. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 2003;46(9):751-5.
  • Di GE, Schaefer C, Mastroiacovo PP, Cournot MP, Benedicenti F, Reuvers M, Occupati B, Robert E, Bellemin B, Addis A, Arnon J, Clementi M. Adverse effects of prenatal methimazole exposure. Teratology. 2001;64(5):262-6.
  • Schaefer C. Risiken gastroenterologischer Pharmakotherapie in der Schwangerschaft. Hamburger Arbeitsgemeinschaft fuer Gastroenterologie. 2000:1-2.
  • Robert E, Vial T, Schaefer C, Arnon J, Reuvers M. Exposure to yellow fever vaccine in early pregnancy. Vaccine. 1999;17(3):283-5.
  • Mastroiacovo P, Mazzone T, Addis A, Elephant E, Carlier P, Vial T, Garbis H, Robert E, Bonati M, Ornoy A, Finardi A, Schaffer C, Caramelli L, Rodriguez-Pinilla E, Clementi M. High vitamin A intake in early pregnancy and major malformations: a multicenter prospective controlled study. Teratology. 1999;59(1):7-11.
  • Schaefer C, Amoura-Elefant E, Vial T, Ornoy A, Garbis H, Robert E, Rodriguez-Pinilla E, Pexieder T, Prapas N, Merlob P. Pregnancy outcome after prenatal quinolone exposure. Evaluation of a case registry of the European Network of Teratology Information Services (ENTIS). Eur J Obstet Gynecol Reprod Biol. 1996;69(2):83-9.
  • McElhatton PR, Garbis HM, Elefant E, Vial T, Bellemin B, Mastroiacovo P, Arnon J, Rodriguez-Pinilla E, Schaefer C, Pexieder T, Merlob P, Dal Verme S. The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants. A collaborative study of the European Network of Teratology Information Services (ENTIS). Reprod Toxicol. 1996;10(4):285-94.
  • Bunjes R, Schaefer C, Holzinger D. Clonidine and breast-feeding. Clin Pharm. 1993;12(3):178-9.
  • Schaefer C, Peters PW. Intrauterine diethyltoluamide exposure and fetal outcome. Reprod Toxicol. 1992;6(2):175-6.
  • Schaefer C, Bunjes R. Arzneimitteltherapie in der Stillzeit. Gynakol Prax. 1991;15:453-6.
  • Kamilli I, Gresser U, Schaefer C, Zöllner N. Allopurinol in breast milk. In: Harkness RA, Elion GB, Zöllner N, editors. Purine and Pyrimidine Metabolism in Man VII. Advances in Experimental Medicine an Biology. 309A. Boston, MA: Springer; 1991. p. 143-5.
  • Schaefer C, Bunjes R. Medikamente in der Schwangerschaft und Stillzeit. Dtsch Arztebl. 1990;87(6):A372-A9.
  • Schaefer C, Spielmann H. Kokain in der Schwangerschaft: ein zweites Contergan? Geburtshilfe Frauenheilkd. 1990;50:899-900.
  • Schaefer C, Bunjes R. Arzneimitteltherapie in der Stillzeit. Padiatr Prax. 1990;40:641-4.
  • Schaefer C. Marcumar in der Muttermilch (Leserbrief). Padiatr Prax. 1990;40:530.